- |||||||||| Focus V (anlotinib) / Advenchen, Sino Biopharm
Clinical, Journal, HEOR, Cost-effectiveness, Cost effectiveness, Metastases: Cost-effectiveness analysis of anlotinib as a third-line or further treatment for advanced non-small cell lung cancer in China. (Pubmed Central) - Sep 11, 2023 The cost-effectiveness acceptability curves showed that the base-case analysis results were relatively stable. Considering the clinical efficacy, safety, and cost-effectiveness of anlotinib, it may be a valuable third-line or further treatment for advanced NSCLC in China.
- |||||||||| Focus V (anlotinib) / Advenchen, Sino Biopharm
Journal: Anlotinib Attenuates Liver Fibrosis by Regulating the Transforming Growth Factor ?1/Smad3 Signaling Pathway. (Pubmed Central) - Sep 8, 2023 In animal experiments, anlotinib showed protective effects on the CCl4-induced liver damage, including ameliorating liver inflammation, reversing liver fibrosis and reducing liver enzymes. This is a very good signal, anlotinib may be useful for halting or reversing the progression of liver fibrosis and could be employed in the development of novel therapeutic drugs for the management of chronic liver diseases.
- |||||||||| Anniko (penpulimab) / Akesobio, Sino Biopharm, Focus V (anlotinib) / Advenchen, Sino Biopharm
Trial completion date, Trial initiation date, Trial primary completion date, Metastases: ALTER-HN005: Anlotinib, Penpulimab and Capecitabine in Recurrent/Metastatic Nasopharyngeal Carcinoma (clinicaltrials.gov) - Sep 6, 2023 P2, N=110, Not yet recruiting, These cases suggest that osimertinib is a promising treatment option for patients with EGFR 19 deletion-mutated lung adenocarcinoma and bone metastases, although further clinical studies are needed to confirm its efficacy. Trial completion date: Jun 2025 --> Oct 2025 | Initiation date: Jun 2023 --> Oct 2023 | Trial primary completion date: Jun 2024 --> Oct 2024
- |||||||||| Focus V (anlotinib) / Advenchen, Sino Biopharm
Is Neoadjuvant Chemotherapy Useful in Primary Pulmonary Artery Synovial Sarcoma? (In-Person) - Sep 4, 2023 - Abstract #CAP2023CAP_523; Anlotinib was administered orally during the period of chemotherapy...Histopathologic features of viable tumor were similar to the previous biopsy. Our experience suggests that neoadjuvant chemotherapy should be considered to improve resectability in cases of borderline resectable pulmonary artery sarcoma.
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD)
Hand-foot syndrome induced by Pembrolizumab for non-small cell lung cancer (e-Poster Hall) - Aug 30, 2023 - Abstract #EADV2023EADV_2365; HFS has been described in the literature as an uncommon side effect of many anti-tumor drugs including pembrolizumab but always in combination with other drugs such as capecitabine, lenvatinib and anlotinib. There are no reports in literature concerning the development of HFS as side effect of pembrolizumab in monotherapy, thus our report may help researcher to improve the side effect profile of the immunotherapeutic agent that is nowadays considered a novel and encouraging tool against cancer.
- |||||||||| Focus V (anlotinib) / Advenchen, Sino Biopharm
Preclinical, Journal: Anlotinib exerts an anti-T-cell acute lymphoblastic leukemia effect in vitro and in vivo. (Pubmed Central) - Aug 28, 2023 There are no reports in literature concerning the development of HFS as side effect of pembrolizumab in monotherapy, thus our report may help researcher to improve the side effect profile of the immunotherapeutic agent that is nowadays considered a novel and encouraging tool against cancer. The present study showed that anlotinib may be a promising anti-T-ALL candidate drug, and simultaneous reduction of the protein levels of both ICN1 and c-Myc may contribute to the anti-T-ALL efficacy of anlotinib.
- |||||||||| Anniko (penpulimab) / Akesobio, Sino Biopharm, Focus V (anlotinib) / Advenchen, Sino Biopharm, TQB2618 / Sino Biopharm
New P1 trial, Monotherapy, Metastases: A Clinical Study of TQB2618 Injection Monotherapy and Combination Regimen (With Penpulimab Injection (clinicaltrials.gov) - Aug 25, 2023 P1, N=75, Not yet recruiting,
- |||||||||| Review, Journal: Small molecule protein kinase inhibitors approved by regulatory agencies outside of the United States. (Pubmed Central) - Aug 21, 2023
Although the efficacy of imatinib in the treatment of chronic myelogenous leukemia in the United States in 2001 was the main driver of protein kinase inhibitor drug discovery, this was preceded by the approval of fasudil (a ROCK antagonist) in Japan in 1995 for the treatment of cerebral vasospasm...One-third of the 21 internationally approved drugs are not compliant with Lipinski's rule of five for orally bioavailable drugs. The rule of five relies on four parameters including molecular weight, number of hydrogen bond donors and acceptors, and the Log of the partition coefficient.
- |||||||||| Focus V (anlotinib) / Advenchen, Sino Biopharm
Journal: "One-stop" synergistic strategy for hepatocellular carcinoma postoperative recurrence. (Pubmed Central) - Aug 11, 2023 Subsequently, SQAP was constructed by loading black phosphorus nanosheets (BPNSs) and anlotinib hydrochloride (AL3818) based on SQ-50...Furthermore, in vivo studies indicated that the NIR-assisted SQAP prevented local recurrence of ectopic HCC after surgical resection, achieved through the synergistic effect of mPTT and molecular targeted therapy. Thus, the multifunctional SQAP provides a "one-stop" synergistic strategy for HCC postoperative recurrence, showing great potential for clinical application.
- |||||||||| Focus V (anlotinib) / Advenchen, Sino Biopharm
Trial completion date, Trial primary completion date, Monotherapy, Metastases: Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS) (clinicaltrials.gov) - Aug 1, 2023 P3, N=325, Active, not recruiting, This indicate that comprehensive treatment including immunotherapy may be helpful for inoperable DMPM patients with nasopharyngeal carcinoma accompanied with paraneoplastic syndromes. Trial completion date: Apr 2023 --> Apr 2024 | Trial primary completion date: Dec 2022 --> Dec 2023
- |||||||||| Focus V (anlotinib) / Advenchen, Sino Biopharm
Enrollment open, Metastases: Anlotinib Maintenance Treatment for Advanced Soft Tissue Sarcoma (clinicaltrials.gov) - Aug 1, 2023 P2, N=48, Recruiting, Trial completion date: Apr 2023 --> Apr 2024 | Trial primary completion date: Dec 2022 --> Dec 2023 Active, not recruiting --> Recruiting
- |||||||||| Review, Journal: Indole Antitumor Agents in Nanotechnology Formulations: An Overview. (Pubmed Central) - Jul 29, 2023
Additionally, new drug delivery systems have been developed to protect the active principle from degradation and to direct the drug to the specific site for clinical use, thus reducing its toxicity. In the present work is an updated review of the recently approved indole-based anti-cancer agents and the nanotechnology systems developed for their delivery.
- |||||||||| Tevimbra (tislelizumab) / BeiGene, Novartis, Focus V (anlotinib) / Advenchen, Sino Biopharm
Combinationof Anlotinib and Tislelizumab for Lung Adenocarcinoma: Effects on Metabolic and Flora Microenvironment (Exhibit Hall) - Jul 29, 2023 - Abstract #IASLCWCLC2023IASLC_WCLC_2468; The results of this study show that combination therapy can effectively activate immune cells, inhibit neovascularization, and cause changes in intestinal flora and metabolites in vivo. In addition, we identified combination therapy-related genes and signaling pathways, which provide a basis for clinical individualization and comprehensive treatment.
- |||||||||| Focus V (anlotinib) / Advenchen, Sino Biopharm
Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Preliminary results from a multi-cohort, multi-center phase II trial (ALTER-G-001) () - Jul 27, 2023 - Abstract #ESMO2023ESMO_3113; P2 B (ESCC): anlotinib, cisplatin (60-750 mg/m2, iv, d1/d1-3), paclitaxel (135 mg/m2, iv, d1) or docetaxel (75 mg/m2, iv, d1)...50 pts had TEAEs and grade 3/4 TEAEs (28.4%) mainly included neutropenia (13.5%), hypertension (6.8%) and white blood cell decreased (5.4%). Conclusions Anlotinib plus chemotherapy as 1L treatment has shown promising efficacy and acceptable safety and may be a favorable option for advanced LMs GI tumors, especially for PC.
|